NCT05118841: Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors

NCT05118841
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated or uncontrolled central nervous system (CNS) involvement
https://ClinicalTrials.gov/show/NCT05118841

Comments are closed.

Up ↑